Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients

Abstract

Immunotherapy greatly improves clinical outcomes in treated patients with cancer. However, the long-lasting immune response and long duration of therapy could induce long-term adverse effects owing to the chronic inflammation induced. Type 2 diabetes is now recognized as an inflammatory disease. In addition, immunotherapy is concerned with increase in the production of tumor necrosis factor-&agr;, interleukin-2, and interferon-&ggr;, which are involved in the inflammatory process. Based on these observations, we hypothesized that anti-programmed cell death-1 (anti-PD-1) and/or anticytotoxic T-lymphocyte-associated protein-4 therapy could contribute to type 2 diabetes genesis in treated patients. Therefore, to evaluate this hypothesis, we studied HbA1c levels during follow-up in patients treated with anti-PD-1 and/or anticytotoxic T-lymphocyte-associated protein-4 therapy. A prospective and observational study was performed in an oncodermatology department (Saint-Louis Hospital, Paris, France) from March 2015 to February 2017. Sixty-two patients meeting the inclusion criteria were enrolled. Forty-three patients had paired HbA1c measurements during their follow-up period and were analyzed. The median follow-up was 3 months. We noted an increase in HbA1c levels from 5.3% [interquartile range (IQR): 5.1–5.5; range: 4.5–6.2) to 5.45% (IQR: 5.2–5.7; range: 4.7–6.2; P=0.037). This observation was confirmed in the subgroup of patients who did not receive concomitant glucocorticoids;…

Overview

Integrity signals

Registry

Crossref · 10.1097/cmr.0000000000000585

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Cited by

See all 10

Metadata

Authors
Gauci, M.-L., Boudou, P., Squara, P.-A., Delyon, J., Allayous, C., Mourah, S., Resche-Rigon, M., Lebbé, C., Baroudjian, B., & Gautier, J.-F.
Affiliations
  • Inserm (FR)
  • Assistance Publique – Hôpitaux de Paris (FR)
  • AP-HP Department of Statistics
  • AP-HP Department of Dermatology, INSERM U976
Corresponding author
Gauci, Marie-Léa
Venue
Melanoma Research
Published
2019-06
Volume
29
Issue
3
Pages
328-332
ISSN
0960-8931 (ISSN-L)
OpenAlex
W2919158317
Cited by
10
References
19
Citations by year
2026: 2 · 2025: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2
FWCI
0.63
Type
journal article
Language
en
Open access
closed
Locations
  • Melanoma Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Dermatology › Skin Diseases and Diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 blockade, HbA1c, type 2 diabetes, glucose metabolism, cancer immunotherapy, glucocorticoids, melanoma, chronic inflammation, adverse effects of immunotherapy
MeSH terms
Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Prognosis, Prospective Studies, Skin Neoplasms, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. https://app.cochat.ai/papers/10.1097/cmr.0000000000000585
The paper
Gauci, M.-L., Boudou, P., Squara, P.-A., Delyon, J., Allayous, C., Mourah, S., Resche-Rigon, M., Lebbé, C., Baroudjian, B., & Gautier, J.-F. (2019). Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Research. https://doi.org/10.1097/cmr.0000000000000585

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.